Enanta Pharmaceuticals
Market Cap
US$1.4b
Last Updated
2019/08/21 00:47 UTC
Data Sources
Company Financials +
Executive Summary
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases.
Snowflake
Fundamentals
Excellent balance sheet with acceptable track record.
Risks
- Enanta Pharmaceuticals has significant price volatility in the past 3 months.
Share Price & News
How has Enanta Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.0%
NasdaqGS:ENTA
0.2%
US Biotechs
0.2%
US Market
1 Year Return
-21.0%
NasdaqGS:ENTA
-9.1%
US Biotechs
-0.7%
US Market
ENTA underperformed the Biotechs industry which returned -7.3% over the past year.
ENTA underperformed the Market in United States of America which returned 0.3% over the past year.
Share holder returns
| ENTA | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.0% | 0.2% | 0.2% |
| 30 Day | -12.3% | 0.9% | -2.7% |
| 90 Day | -21.5% | 2.4% | 1.6% |
| 1 Year | -21.0%-21.0% | -8.4%-9.1% | 1.6%-0.7% |
| 3 Year | 218.0%218.0% | 8.3%4.6% | 40.0%30.9% |
| 5 Year | 65.0%65.0% | 4.5%-0.3% | 53.8%36.8% |
Price Volatility Vs. Market
How volatile is Enanta Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Too Much Debt?2 weeks ago | Simply Wall St
Can You Imagine How Chuffed Enanta Pharmaceuticals's (NASDAQ:ENTA) Shareholders Feel About Its 248% Share Price Gain?1 month ago | Simply Wall St
Don't Sell Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Before You Read ThisValuation
Is Enanta Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?
21.84x
Price to Earnings (PE) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for Enanta Pharmaceuticals to establish if it is available at moderate discount.
Unable to calculate intrinsic value for Enanta Pharmaceuticals to establish if it is available at substantial discount.
Price Based on Earnings
Enanta Pharmaceuticals is overvalued based on earnings compared to the US Biotechs industry average.
Enanta Pharmaceuticals is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
Enanta Pharmaceuticals earnings are not expected to grow next year, we can't assess if its growth is good value.
Price Based on Value of Assets
Enanta Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.
Next Steps
Future Growth
How is Enanta Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?
-67.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Enanta Pharmaceuticals's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Enanta Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
Enanta Pharmaceuticals's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Enanta Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Enanta Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Enanta Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Next Steps
Past Performance
How has Enanta Pharmaceuticals performed over the past 5 years?
0.6%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Enanta Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
Enanta Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the 5-year average.
Enanta Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the US Biotechs industry average.
Return on Equity
Enanta Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
Enanta Pharmaceuticals used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.
Return on Capital Employed
Enanta Pharmaceuticals has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Enanta Pharmaceuticals's financial position?
Financial Position Analysis
Enanta Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Enanta Pharmaceuticals's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Enanta Pharmaceuticals's level of debt (0.4%) compared to net worth is satisfactory (less than 40%).
The level of debt compared to net worth has increased over the past 5 years (0.1% vs 0.4% today).
Debt is well covered by operating cash flow (5602.8%, greater than 20% of total debt).
Enanta Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.
Balance Sheet
Low level of unsold assets.
Debt is covered by short term assets, assets are 277.2x debt.
Next Steps
Dividend
What is Enanta Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Enanta Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Enanta Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Enanta Pharmaceuticals has not reported any payouts.
Unable to verify if Enanta Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Enanta Pharmaceuticals has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Enanta Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
15.9yrs
Average management tenure
CEO
Jay Luly (63yo)
16.1yrs
Tenure
US$4,508,737
Compensation
Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer and President of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxford Bioscien ...
CEO Compensation Analysis
Jay's remuneration is about average for companies of similar size in United States of America.
Jay's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
15.9yrs
Average Tenure
64yo
Average Age
The average tenure for the Enanta Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
4.6yrs
Average Tenure
61.5yo
Average Age
The tenure for the Enanta Pharmaceuticals board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Paul Mellett (64yo)
Senior VP of Finance & Administration and CFO
- Tenure: 15.9yrs
- Compensation: US$1.42m
Jay Luly (63yo)
President
- Tenure: 16.1yrs
- Compensation: US$4.51m
Yat Or (67yo)
Senior VP of Research & Development and Chief Scientific Officer
- Tenure: 19.8yrs
- Compensation: US$1.52m
Nathaniel Gardiner (65yo)
Senior VP
- Tenure: 5.3yrs
- Compensation: US$1.38m
Nathalie Adda (53yo)
Senior VP & Chief Medical Officer
- Tenure: 4.2yrs
- Compensation: US$1.51m
Carol Miceli
Director of Investor Relations
- Tenure: 0.0yrs
Board Members
Bruce L. Carter (76yo)
Non-Executive Chairman
- Tenure: 3.7yrs
- Compensation: US$394.19k
Jay Luly (63yo)
President
- Tenure: 16.1yrs
- Compensation: US$4.51m
Terry Vance (61yo)
Independent Director
- Tenure: 8.2yrs
- Compensation: US$374.19k
Kris Peterson (60yo)
Independent Director
- Tenure: 1.9yrs
- Compensation: US$205.85k
George Golumbeski (62yo)
Independent Director
- Tenure: 5.5yrs
- Compensation: US$366.69k
Lesley Russell (58yo)
Director
- Tenure: 2.8yrs
- Compensation: US$361.69k
Company Information
Enanta Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Enanta Pharmaceuticals, Inc.
- Ticker: ENTA
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.424b
- Shares outstanding: 19.68m
- Website: https://www.enanta.com
Number of Employees
Location
- Enanta Pharmaceuticals, Inc.
- 500 Arsenal Street
- Watertown
- Massachusetts
- 2472
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ENTA | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Mar 2013 |
| 9EP | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Mar 2013 |
Biography
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/08/21 00:47 |
| End of Day Share Price | 2019/08/20 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.